Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RegeneCyte
- Development stage
- Approved
- Lead developer
- StemCyte
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
RegeneCyte is an allogeneic cell therapy product derived from human umbilical cord blood (hUCB), developed by StemCyte. It consists of a concentrated population of hematopoietic progenitor cells (HPC) and other mononuclear cells. The product is currently being evaluated in Phase II and Phase III clinical trials for the treatment of Post-COVID Condition (also known as Long COVID), with a primary focus on reducing chronic fatigue. The therapeutic rationale is based on the immunomodulatory and regenerative properties of cord blood-derived cells, which are hypothesized to resolve persistent systemic inflammation and promote tissue repair in patients suffering from post-viral syndromes.
- Brand names
- RegeneCyte
- Other names
- Human Umbilical Cord BloodhUCBHPC, Cord BloodHematopoietic Progenitor Cells, Cord Blood
Beyond the preview
Go deeper on RegeneCyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RegeneCyte.